Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.

Tanox Inc (under license from Biogen Idec, formerly Biogen Inc) is developing ibalizumab, an intravenous, humanized, monoclonal antibody specific for CD4, for the potential treatment of HIV infection. In August 2006, the FDA advised Tanox to conduct additional dose-finding studies, from which data could potentially be used in a BLA filing. Ibalizumab had reached phase II clinical trials; however, there are currently no ongoing clinical trials.